Associations - EGFR G719X

BIOMARKER:

EGFR G719X

Entrez ID:

Related biomarkers:

‹

›

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

EGFR G719X EGFR G719X	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR G719X EGFR G719X	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: C2 – Inclusion Criteria osimertinib Sensitive : C2
EGFR G719X EGFR G719X	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: C2 – Inclusion Criteria erlotinib Sensitive : C2
EGFR G719X EGFR G719X	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: C2 – Inclusion Criteria gefitinib Sensitive : C2
EGFR G719X EGFR G719X	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3
EGFR G719X EGFR G719X	Non Small Cell Lung Cancer NSCLC	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3
EGFR G719X EGFR G719X	Lung Cancer Lung Cancer	pan-ErbB inhibitor Sensitive: D – Preclinical pan-ErbB inhibitor Sensitive : D